Studies Sensitivity of the Gut in Bowel Disease and Irritable Bowel Syndrome
Collects samples from adults with bowel conditions, including IBS, colitis, Crohn's disease and healthy people.
Plain-language title generated from the registry record
Registry title: Visceral Sensitivity in IBD (Irritable Bowel Disease) and IBS (Irritable Bowel Syndrome)
Key facts
- Where
- Leuven, BelgiumSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with irritable bowel syndrome (IBS), ulcerative colitis or Crohn's disease, and for healthy volunteers without belly complaints.
- Age
- 18 Years to 65 Years
- Sex
- All sexes can join.
- Disease stage
- IBS by Rome III criteria with no obvious physical cause. Ulcerative colitis or Crohn's disease, either active or in remission. Remission must be confirmed by at least one sigmoidoscopy.
- Earlier treatment
- Medicines that affect gut movement or sensation must be stopped at least 24 hours before the study.
Main reasons for not taking part
- Severe kidney disease
- Severe liver disease
- Thyroid abnormalities
- Impaired blood clotting
- Abdominal surgery (an uncomplicated appendectomy is allowed)
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT02421705, who can take part
Where in Belgium
- University Hospitals LeuvenLeuven, BelgiumContact: Lien Beullens, MScTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- KU Leuven
- Trial code
- NCT02421705
- Record updated
- 22 October 2026
- Original description
Aim:Read full original descriptionShow less
Visceral Sensitivity in IBD and IBS: Role of Inflammation, Immune Activity and Genetic Factors
Aim:
More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.
Inclusion: For group 1: IBS; Irritable Bowel Syndrome (IBS) (ROME III criteria); No obvious organic explanation for the IBS symptoms; Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study; Group 2: active ulcerative colitis 1. diagnosis of ulcerative colitis (Confirmed by at least one sigmoidoscopy) 3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study; Group 3: ulcerative colitis in remission (3a: with IBS symptoms, 3b: without IBS symptoms); diagnosis of ulcerative colitis (Confirmed by at least one sigmoidoscopy); remission is confirmed by at least one sigmoidoscopy; Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study; Only for group 3a:; Rome III criteria for IBS; Group 4: Healthy controls No abdominal (pain) complaints; Group 5: active Crohn's disease; diagnosis of Crohn's disease (Confirmed by at least one sigmoidoscopy) 3. Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study; Group 6: Crohn's disease in remission (6a: with IBS symptoms, 6b: without IBS symptoms); diagnosis of Crohn's disease (Confirmed by at least one sigmoidoscopy); remission is confirmed by at least one sigmoidoscopy; Medication which affects the gastrointestinal motility or perception should be stopped at least 24 hours before the study.
Exclusion: co-morbidity: severe kidney- and/or liver disease or thyroid abnormalities and impaired clotting; For all groups:; Abdominal chirurgy (except for an uncomplicated appendectomy).